MIMS Doctor spoke to Dr Kho Sze Shyang, of Sarawak General Hospital, who won not one, but two awards at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), held in Yokohama, Japan. The two papers that Kho submitted won him the IASLC International Mentorship Program and the WCLC 2017 Developing Nation Travel Awards.
Integrating robust smoking cessation programs with organized low-dose CT (LDCT) lung cancer screening may decrease mortality rates while being relatively cost-effective, according to a modelling study.
Customizing chemotherapy (CT) treatment based on BRCA1 expression levels of post-operative patients with stage II/III non-small-cell lung cancer (NSCLC) does not affect overall survival (OS) versus standard treatment, say researchers.
On-the-ground education focused on changing knowledge, beliefs and attitudes towards cancer may be key to reducing disproportionately high mortality rates among underserved minority communities, say researchers.
The introduction of early specialist palliative care for patients recently diagnosed with malignant pleural mesothelioma (MPM) has no impact on the quality of life (QOL) scores, reveals a research presented by Professor Fraser Brims, of Curtin University Australia, at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), held recently in Yokohama, Japan.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.